Physician profile
Jonathan E Ross
NPI 1538150578
$4,280.42
in general payments reported to CMS, 2019-2025
16 companies · $1,945 in 2025
The $1,945 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $231 · 2021: $429 · 2022: $745 · 2023: $326 · 2024: $441 · 2025: $1,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,027 · Travel and Lodging: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,026.69 |
| Travel and Lodging | $685.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,554.83 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $485.43 | 2022-2025 | Miebo, Xiidra, Infuse |
| Coopervision INC. | $396.95 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Allergan, INC. | $377.17 | 2019-2022 | |
| Oyster Point Pharma, INC. | $232.02 | 2022-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $190.70 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $165.35 | 2020-2025 | Tryptyr |
| Notal Vision, INC. | $145.49 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $140.20 | 2019-2021 | |
| Abbvie INC. | $133.67 | 2022-2024 | Alphagan P, Lumigan, Vuity |
| Novartis Pharmaceuticals Corporation | $133.35 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $112.92 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $97.49 | 2021-2025 | Cequa |
| Shire North American Group INC | $44.32 | 2019 | |
| Dompe US, INC. | $39.80 | 2025 | Oxervate |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $30.73 | 2024-2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.